×

Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd are pioneering a new class of synthetic anti-infectives to address the urgent global health threat posed by superbugs and emerging viral pathogens.

RECCE® 327 and RECCE® 529 have been designed with a unique mechanism of action, with the goal of re-empowering physicians in their potential of an effective treatment that may be used repeatedly against a broad range of bacteria and viruses. RECCE® 529 is a new synthetic polymer formulation with indication against viruses.

Spotlight Videos